FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 329:580-582 August 19, 1993 Number 8 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Fisher, R. I. PubMed Citation

To the Editor: Several pieces of data are needed to interpret the conclusion of Fisher et al. (April 8 issue)¹ that CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) "remains the best available treatment for patients with advanced-stage intermediate-grade or high-grade non-Hodgkin's lymphoma." First, how many centers contributed patients, and how many patients did the average center assign to each regimen? The study included 233 patients treated with ProMACE-CytaBOM (prednisone, doxorubicin, cyclophosphamide, and etoposide followed by cytarabine, bleomycin, vincristine, and methotrexate with leucovorin rescue), and the complete-response rate was 56 percent, a level 30 percent lower than that reported by the National . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Youngberg, G. A., Karnad, A., Busch, M. P., Murphy, E., Nemo, G., Zucker-Franklin, D., Pancake, B. A. (1993). More on HTLV tax and Mycosis Fungoides. NEJM 329: 2035-2036 [Full Text]